Rookie FDA Mistake By Australian Cannabis Company Investigating BO Puts Investors All In A Sweat

1w
2m read
Summary

What’s going on with this ASX cannabis share? Unfortunately, the ASX cannabis share has been dealt a blow from the regulator. The company is currently in the process of seeking US Food and Drug Administration (FDA) approval for the anticholinergic/antimuscarinic drug for the treatment of primary axillary hyperhidrosis. Judging by the performance of the ASX cannabis share today, investors appear frustrated that the company has failed at such a seemingly simple step and now must wait upwards of nine months to go again. In morning trade, the cannabis-focused ASX dermatology share is down a massive 36% to 11.5 cents.

Article Preview

It’s certainly stupid season when it comes to cannabis in Australia at the moment.

 

Motley Fool reports

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price has returned from its trading halt and crashed deep into the red.

In morning trade, the cannabis-focused ASX dermatology share is down a massive 36% to 11.5 cents.

What’s going on with this ASX cannabis share?

Investors have been selling Botanix shares after the company provided an update on...

Read the full article @ Cannabis Law Report